A critical look at CAR-T therapeutics
Increasing the capacity, efficiency and robustness of biomanufacturing for multiple late-stage clinical and commercial-scale cell-based products is THE critical challenge for the industry moving forward.
It is crucial that we as an industry come together to drive the evolution and uptake of novel automated tools, guidelines and standards.
This is what our working group is Edinburgh is doing.
This is what we are reflecting upon in our recent blog – where automated methods can be implemented in the autologous CAR-T therapy process.